AMTX vs PATH
Aemetis Inc (AMTX) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Aemetis Inc (AMTX) is a specialty chemicals company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported AMTX revenue for 2023-12-31 was $77.2M. Net income was -$46.4M. Revenue was up 174.6% from 2022-12-31 to 2023-12-31. AMTX currently screens at market cap $158.3M.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
AMTX currently screens at market cap $158.3M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the AMTX and PATH stock pages for the full models.
Not investment advice.